Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluoxetine (drug) Clear all
Completed Phase 4 Interventional Results available

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

NCT00806234
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 19 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

NCT01672255
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure
Interventions
Fluoxetine, Placebo control
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Results available

Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa

NCT00288574
View directory record Official record
Conditions
Anorexia Nervosa, Eating Disorders
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Maintenance Interpersonal Psychotherapy for Sustaining Remission of Depression

NCT00227981
View directory record Official record
Conditions
Depression
Interventions
Interpersonal Psychotherapy, Fluoxetine
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

A Study in Relapse Prevention of Treatment-Resistant Depression

NCT00958568
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Olanzapine and Fluoxetine combination (OFC), Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
36
States / cities
Pasadena, California • Sherman Oaks, California • Wildomar, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Sep 28, 2026, 10:13 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 4 Interventional

Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)

NCT01185977
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Sep 28, 2026, 10:13 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

NCT05948553
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fluoxetine to Reduce Intubation and Death After COVID19 Infection

NCT04377308
View directory record Official record
Conditions
COVID-19, Cytokine Storm
Interventions
Fluoxetine
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa

NCT00733525
View directory record Official record
Conditions
Eating Disorders
Interventions
Cognitive Behavioral Therapy, Fluoxetine, Guided Self-Help
Behavioral · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Palo Alto, California • Minneapolis, Minnesota • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Results available

Fluoxetine Treatment of Depression in Down Syndrome

NCT05458479
View directory record Official record
Conditions
Down Syndrome, Depression
Interventions
Fluoxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 28, 2026, 10:13 AM EDT
Active, not recruiting Early Phase 1 Interventional

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

NCT05634707
View directory record Official record
Conditions
Primary Brain Tumor, Brain Tumor, Recurrent
Interventions
Fluoxetine, Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
24 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Diego, California • Stanford, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 28, 2026, 10:13 AM EDT
Terminated Phase 4 Interventional Results available

Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder

NCT00592852
View directory record Official record
Conditions
Pediatric Bipolar Disorder, Pediatric OCD
Interventions
fluoxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 28, 2026, 10:13 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 4 Interventional

Relapse Prevention for Bipolar Type-II Disorder

NCT00044616
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Fluoxetine, Lithium
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 28, 2026, 10:13 AM EDT
Withdrawn Phase 2 Interventional

RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke

NCT01963832
View directory record Official record
Conditions
Severe Stroke With Affected Arm Motor Function
Interventions
Fluoxetine, Placebo, eCMIT, Usual Care
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2015 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Adaptive Treatment Strategy for Adolescent Depression

NCT01802437
View directory record Official record
Conditions
Adolescent Depression
Interventions
Fluoxetine, Increased Dose of Interpersonal Psychotherapy, Continue to Receive Initial Dose of Interpersonal Psychotherapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional Results available

Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures

NCT05575128
View directory record Official record
Conditions
Cardiac Surgery, Older Adults, Depression, Anxiety
Interventions
Behavioral activation, Medication optimzation, Care as usual
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD

NCT04131829
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Fluoxetine - immediate treatment, Fluoxetine - delayed treatment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts

NCT00142779
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders
Interventions
Fluoxetine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 28, 2026, 10:13 AM EDT
Withdrawn Early Phase 1 Interventional

Fluoxetine Prevention Trial

NCT01615055
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
Fluoxetine, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

NCT02929667
View directory record Official record
Conditions
Epilepsy, SUDEP
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Rup Kamal Sainju
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 28, 2026, 10:13 AM EDT